jeudi 18 mai 2017

Onco Actu du 18 mai 2017 - Spécial ASCO ASCO (général) - Industriels

Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting [Pfizer]

Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio [Amgen]

Data from Clinical Studies of NewLink Genetics' Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017 [NewLink Genetics]

Roche presents the first Phase I efficacy and safety data on CEA-TCB (CEA CD3 TCB), a novel T-cell bispecific antibody targeting solid tumours [Roche]

Bristol-Myers Squibb Research Showcases Expansive Oncology Clinical Development Program and Commitment to Exploring Novel Combinations at ASCO 2017 [BMS]

Lilly to Present Results from Pivotal Breast Cancer Study of Abemaciclib and New Portfolio Data at ASCO 2017 [Lilly]

ASCO 2017: Janssen to Present 19 Abstracts in Prostate Cancer and a Spectrum of Blood Cancers; Includes Data on Abiraterone Acetate, Daratumumab and Ibrutinib [Janssen]

AbbVie to Present Latest Clinical Study Results in Hematology and Solid Tumor Research at the 53rd American Society of Clinical Oncology (ASCO) Annual Meeting [AbbVie]

Astellas Announces Oncology Portfolio Updates [Astellas]

Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo [EndPoints]

5.5.10 ASCO (hémato)

bluebird bio to Present Updated Clinical Results from Novel Anti-BCMA CAR T Cell Therapy bb2121 at American Society of Clinical Oncology (ASCO) Annual Meeting [bluebird bio]

Celgene, Agios Update Blood Cancer Drug Study Results in ASCO '17 Abstract [The Street]

GlycoMimetics stock rockets up on the latest ‘breakthrough’ title in cancer R&D [EndPoints]

Celgene leukemia drug extends survival in early stage trial [Reuters]

5.5.12 ASCO (médico-éco)

More Cancers Diagnosed at Early Stage Following Increase in Health Insurance Coverage [ASCO]

Obamacare Helped Americans Detect Cancer Earlier [Bloomberg]

5.5.13 ASCO (divers)

Can cashews keep colon cancer patients alive? Study says yes — but cautions abound [STAT]

HPV Vaccination May Reduce Oral HPV Infections – But Still Under-Utilized [ASCO]

Chance of Colon Cancer Recurrence Nearly Cut in Half in People Who Eat Nuts [ASCO]

Vaccine may cut HPV infections, an oral cancer risk, in men [AP]

Eating tree nuts may cut risk that colon cancer will return: study [Reuters]

5.5.14 ASCO (vessie)

Merck says test shows Keytruda improves survival for bladder cancer patients [Reuters]

5.5.17 ASCO (pancréas)

Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO [Halozyme]

5.5.2 ASCO (sein)

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting [Puma]

Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting [Puma]

Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting [Puma]

Pfizer drug from Medivation deal shows promise in breast cancer: study [Reuters]

5.5.4 ASCO (immunothérapies)

Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 and JCAR014 at the 2017 American Society of Clinical Oncology Annual Meeting [Juno]

Kite Announces Presentations on Its Lead CAR-T Therapy Development Program at the 2017 American Society of Clinical Oncology Annual Meeting [Kite]

Bluebird, Kite and Juno Delivering CAR-T Cancer Study Updates to ASCO '17 Meeting [The Street]

5.5.5 ASCO (gastro-intestinal)

Healthy Lifestyle After Colon Cancer Diagnosis Helps Patients Live Longer [ASCO]

5.5.7 ASCO (gynéco)

ImmunoGen Announces New Clinical Data with Mirvetuximab Soravtansine in Ovarian Cancer to be Presented at 2017 ASCO Annual Meeting [ImmunoGen]

ImmunoGen drug moving ahead in single-agent, combination trials [Reuters]

5.5.8 ASCO (poumon)

Targeted Therapy Can Delay Recurrence of Intermediate-Stage Lung Cancer [ASCO]

Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend [The Street]

Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle [EndPoints]

Merck, Incyte immunotherapy combination effective in lung cancer study [Reuters]

5.5.9 ASCO (autres organes)

Drug improves survival of patients with rare cancer by almost a quarter [Cancer Research UK]

Oral Chemotherapy Extends Survival by More Than a Year in Biliary Tract Cancer [ASCO]